LIMN
NASDAQLiminatus Pharma Inc.
Liminatus Pharma Inc. (LIMN) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for LIMN, including 1 SEC filing. The most recent was published Nov 3, 2026.
Financial highlights
Full financials- Net income, TTM
- -$12.52M
- Cash
- $3.02M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks27-50%
2026-05-172026-11-08
Mix690d
- Other3(50%)
- SEC Filings3(50%)
Activity · 52 weeks4031 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECLiminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- PRLiminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price RuleFULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule. As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the applicable minimum bid price requirement for The Nasdaq Global Market). Following an appeal and hearing before the Nasdaq Hearings Panel, the Panel determined to transfer the
- PRLiminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyFULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. ("Synex"), a Korea-based full-service contract research organization ("CRO"), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate. The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) for a Phase 1/2a clinical study in patients with re
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- PRLiminatus Pharma, Inc. Announces Reverse Stock Split of its Common StockFULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-50 (the "Reverse Stock Split"), which was approved by stockholders at the Company’s 2026 Annual Meeting of Stockholders held on August 3, 2026. The Reverse Stock Split will take effect at the close of trading on August 20, 2026, and the Company’s Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the Company’s existing trading symbol "L
- SECSEC Form 10-Q filed by Liminatus Pharma Inc.10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)
- PRLiminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price RequirementFULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the "Panel") has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement. The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, "LIMN." The Nasdaq Capital Market is one
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- INSIDERLarge owner Valetudo Therapeutics Llc acquired 3,448,926 shares, increasing direct ownership by 192% to 5,244,351 units (SEC Form 4)4 - Liminatus Pharma, Inc. (0001971387) (Issuer)
- SECSEC Form DEF 14A filed by Liminatus Pharma Inc.DEF 14A - Liminatus Pharma, Inc. (0001971387) (Filer)
- INSIDERLarge owner Valetudo Therapeutics Llc disposed of 4,373,603 shares, decreasing direct ownership by 71% to 1,795,803 units (SEC Form 4)4 - Liminatus Pharma, Inc. (0001971387) (Issuer)
- INSIDERNew insider Ewon Comfortech Co., Ltd. claimed ownership of 5,500,000 shares (SEC Form 3)3 - Liminatus Pharma, Inc. (0001971387) (Issuer)
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- PRLiminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy PipelineFULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology company focused on next-generation cell therapy technologies. The transaction has been re-structured to allow closing prior to obtaining stockholder approval, with closing now expected to occur on July 2, 2026, subject to the satisfaction or waiver of customary closing conditions. Under the amended terms of the merger agreement, the equity holders
- SECSEC Form PRE 14A filed by Liminatus Pharma Inc.PRE 14A - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECSEC Form S-1 filed by Liminatus Pharma Inc.S-1 - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECSEC Form D filed by Liminatus Pharma Inc.D - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- SECSEC Form 424B3 filed by Liminatus Pharma Inc.424B3 - Liminatus Pharma, Inc. (0001971387) (Filer)
- PRLiminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross ProceedsFULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000 shares of common stock of the Company (the "Existing Warrants"). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000 million shares of common stock (the "New Warrants"). In connection with the exercise, the Company also agreed to reduce the exercise price of the Ex
- SECLiminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Liminatus Pharma, Inc. (0001971387) (Filer)
- PRLiminatus Pharma Announces Nasdaq Delisting NotificationFULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed in the Current Report on Form 8-K filed by the Company on November 25, 2025 with the Securities and Exchange Commission (the "SEC"), on November 19, 2025, the Company received notices from Nasdaq indicating that the Company's listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Rule") and the $15,000,000
LIMN FAQ
7 questionsWhat is the latest news on LIMN?
In the last 30 days Quantisnow tracked 1 wire item for LIMN: 1 SEC filing. The most recent was published on November 3, 2026.Is LIMN profitable?
No. Liminatus Pharma Inc. reported a net loss of $12.52M for the twelve months ended Jun 30, 2026.How much cash and debt does LIMN have?
Liminatus Pharma Inc. reported $3.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does LIMN stock trade?
Liminatus Pharma Inc. (LIMN) is listed on NASDAQ.What sector and industry is LIMN in?
Liminatus Pharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to LIMN?
Notable peers in the same industry include AMGN (Amgen Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare LIMN side-by-side with any of them on Quantisnow.How can I track LIMN on Quantisnow?
Quantisnow aggregates Liminatus Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LIMN to receive live email and push alerts on every new disclosure.